Latest news with #TravisSteed
Business Insider
17-07-2025
- Business
- Business Insider
Bank of America Securities Sticks to Their Buy Rating for Stryker (SYK)
In a report released yesterday, Travis Steed from Bank of America Securities maintained a Buy rating on Stryker, with a price target of $450.00. The company's shares closed yesterday at $390.87. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Steed is a 4-star analyst with an average return of 6.3% and a 60.78% success rate. Steed covers the Healthcare sector, focusing on stocks such as Boston Scientific, Zimmer Biomet Holdings, and Becton Dickinson. Currently, the analyst consensus on Stryker is a Strong Buy with an average price target of $435.94, an 11.53% upside from current levels. In a report released on July 14, BTIG also maintained a Buy rating on the stock with a $413.00 price target. SYK market cap is currently $149.6B and has a P/E ratio of 52.83. Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Most recently, in May 2025, William E. Berry, the VP & CAO of SYK sold 1,241.00 shares for a total of $482,190.55.
Yahoo
10-07-2025
- Business
- Yahoo
Mizuho Lowers PT on Embecta Corp. (EMBC) to $13 From $15, Keeps a Neutral Rating
Embecta Corp. (NASDAQ:EMBC) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On May 23, Mizuho lowered the firm's price target on Embecta Corp. (NASDAQ:EMBC) to $13 from $15, keeping a Neutral rating on the shares. The rating came after analyst day, with the firm telling investors in a research note that the company's long-term guidance calls for sales to stay relatively flat through 2028. An assembly line of medical devices being packed for distribution. Following similar circumstances, Travis Steed from Bank of America Securities maintained a Sell rating on Embecta Corp. (NASDAQ:EMBC) in a report released on May 28, setting a price target of $18.00. Embecta Corp. (NASDAQ:EMBC) provides medical devices used to treat diabetes. The company's offerings include syringes, pen needles, and safety devices fitted with a digital application. While we acknowledge the potential of EMBC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
08-07-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Arcutis Biotherapeutics (ARQT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insulet (PODD – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report) with bullish sentiments. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Insulet (PODD) Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet yesterday and set a price target of $335.00. The company's shares closed last Monday at $300.70. According to Steed is a 4-star analyst with an average return of 7.0% and a 63.3% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Inspire Medical Systems, and Zimmer Biomet Holdings. Insulet has an analyst consensus of Strong Buy, with a price target consensus of $337.56, implying a 12.6% upside from current levels. In a report issued on June 23, TD Cowen also maintained a Buy rating on the stock with a $379.00 price target. Arcutis Biotherapeutics (ARQT) Mizuho Securities analyst Uy Ear maintained a Buy rating on Arcutis Biotherapeutics yesterday and set a price target of $21.00. The company's shares closed last Monday at $13.39. According to Ear is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.8% and a 35.8% success rate. Ear covers the Healthcare sector, focusing on stocks such as Cartesian Therapeutics, ACADIA Pharmaceuticals, and Tectonic Therapeutic. Currently, the analyst consensus on Arcutis Biotherapeutics is a Strong Buy with an average price target of $21.29, a 54.8% upside from current levels. In a report issued on July 2, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $20.00 price target.
Yahoo
15-04-2025
- Business
- Yahoo
How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings
Abbott Laboratories (NYSE:ABT) will release its first-quarter earnings results before the opening bell on Wednesday, April 16. Analysts expect the company to report quarterly earnings at $1.07 per share, up from 98 cents per share in the year-ago period. According to data from Benzinga Pro, Abbott Laboratories projects quarterly revenue at $10.41 billion, compared to $9.96 billion a year earlier. On March 10, Bank of America Securities analyst Travis Steed maintained Abbott with a Buy rating and raised the price target from $133 to $150. With the recent buzz around Abbott Laboratories, some investors may be eyeing potential gains from the company's dividends. Currently, Abbott offers an annual dividend yield of 1.84%. That's a quarterly dividend amount of 59 cents per share ($2.36 a year). So, how can investors exploit its dividend yield to pocket a regular $500 monthly? To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $325,274 or around 2,542 shares. For a more modest $100 per month or $1,200 per year, you would need $65,004 or around 508 shares. To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.36 in this case). So, $6,000 / $2.36 = 2,542 ($500 per month), and $1,200 / $2.36 = 508 shares ($100 per month). View more earnings on ABT Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time. How that works: The dividend yield is computed by dividing the annual dividend payment by the stock's current price. For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40). Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield. ABT Price Action: Shares of Abbott Laboratories gained 0.9% to close at $127.96 on More: Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ABBOTT LABORATORIES (ABT): Free Stock Analysis Report This article How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
15-04-2025
- Business
- Yahoo
How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings
Abbott Laboratories (NYSE:ABT) will release its first-quarter earnings results before the opening bell on Wednesday, April 16. Analysts expect the company to report quarterly earnings at $1.07 per share, up from 98 cents per share in the year-ago period. According to data from Benzinga Pro, Abbott Laboratories projects quarterly revenue at $10.41 billion, compared to $9.96 billion a year earlier. On March 10, Bank of America Securities analyst Travis Steed maintained Abbott with a Buy rating and raised the price target from $133 to $150. With the recent buzz around Abbott Laboratories, some investors may be eyeing potential gains from the company's dividends. Currently, Abbott offers an annual dividend yield of 1.84%. That's a quarterly dividend amount of 59 cents per share ($2.36 a year). So, how can investors exploit its dividend yield to pocket a regular $500 monthly? To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $325,274 or around 2,542 shares. For a more modest $100 per month or $1,200 per year, you would need $65,004 or around 508 shares. To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.36 in this case). So, $6,000 / $2.36 = 2,542 ($500 per month), and $1,200 / $2.36 = 508 shares ($100 per month). View more earnings on ABT Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time. How that works: The dividend yield is computed by dividing the annual dividend payment by the stock's current price. For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40). Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield. ABT Price Action: Shares of Abbott Laboratories gained 0.9% to close at $127.96 on More: Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ABBOTT LABORATORIES (ABT): Free Stock Analysis Report This article How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
